Blockchain Registration Transaction Record

Lantern Pharma's AI Platform Revolutionizes Cancer Drug Development

Lantern Pharma leverages AI platform RADR® to accelerate cancer drug development, reduce costs, and improve patient access to precision oncology treatments like STAR-001 for CNS cancers.

This development matters because traditional cancer drug development takes over a decade and costs hundreds of millions of dollars, limiting patient access to new treatments. By using AI to accelerate drug discovery and clinical trials, Lantern Pharma's approach could significantly reduce both timelines and costs, potentially bringing life-saving precision oncology treatments to patients years sooner. For cancer patients facing limited treatment options, especially those with rare or hard-to-treat cancers like CNS malignancies, this technological advancement represents hope for faster access to targeted therapies that could improve survival rates and quality of life.